

Join Us For Our Upcoming Webinar!

Thursday, October 2, 2025 | 1pm EST

Navigating IgA Nephropathy: Pathogenesis, The Role Of APRIL And The 4-hit Process, And A Patient Case Study

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis. It is characterized by the deposition of galactose-deficient IgA1 (Gd-IgA1) in the glomerular mesangium. The current understanding is that IgA nephropathy occurs due to a multi-hit mechanism, also known as the four-hit process. In addition, multiple observations support the role of APRIL in the pathogenesis of IgAN. Increased APRIL levels have been demonstrated in patients with IgAN and correlate with disease severity (proteinuria and eGFR) and increased expression of Gd-IgA1.¹

Did You Know?

Therapeutic strategies inhibiting APRIL have the potential to limit IgA and, therefore, Gd-IgA1 production by autoimmune-associated plasma cells.¹

Why Attend this Webinar?

The goal of this webinar is to provide a detailed overview of the Four-Hit process as well as explain the role of APRIL in disease pathogenesis.

What You Will Learn

The “four-hit process” of IgAN pathogenesis outlines a process that begins with elevated circulating levels of Gd-IgA1 that trigger autoantibody production. This results in the formation and deposition of immune complexes in the mesangium, leading to inflammation and kidney injury.¹ Elevated serum levels of APRIL are observed in patients with IgAN and correlate with disease severity.¹

Reference:

Cheung CK et al. *Front.Nephrol.* 2024; 3:1346769

**Dr Jai Radhakrishnan is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Hannah Lambert is an employee of OPDC.*

Featuring



Jai Radhakrishnan, MD, MS

Professor of Medicine, Clinical Director of Nephrology Division, Columbia University Medical Center



Hannah N. Lambert, PharmD

Nephrology Senior Medical Science Liaison

NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use independent judgement when reviewing NephU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.

In accordance with updated PhRMA guidelines, no Otsuka provided alcohol will be served at this program.